GeneDx Hit With Class Action Lawsuit Over Fabric Genomics Acquisition Write-off
WGS sits 65% above its 52-week low of $32.21.
Summary
GeneDx Holdings is facing a securities class action lawsuit alleging the company made misleading statements regarding its Fabric Genomics acquisition. This follows the Q1 2026 earnings report on May 4, which disclosed a $31.2 million impairment charge, representing 94% of the acquisition's value, and led to a 49% stock price drop. The lawsuit claims GeneDx misrepresented Fabric Genomics' importance and the durability of its average reimbursement rates. This legal action introduces new financial and reputational risks for the company, adding to the negative sentiment from recent earnings.
At the time of this announcement, WGS was trading at $53.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.